A human monoclonal antibody blocking SARS-CoV-2 infection

Abstract

The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19.

References 24

1. 1.
   A pneumonia outbreak associated with a new coronavirus of probable bat origin · 2020

   No notice
2. 2.

   World Health Organization. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200419-sitrep-90-covid-19.pdf?sfvrsn=551d47fd_4.

   Not in our library

3. 3.
   The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 · 2020

   No notice
4. 4.

   Prabakaran P, et al. Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses. Expert Opin. Biol. Ther. 2009;9:355-368.

   Not in our library10.1517/14712590902763755

5. 5.

   Saphire EO, Schendel SL, Gunn BM, Milligan JC, Alter G. Antibody-mediated protection against Ebola virus. Nat. Immunol. 2018;19:1169-1178.

   Not in our library10.1038/s41590-018-0233-9

6. 6.
   Structural Bases of Coronavirus Attachment to Host Aminopeptidase N and Its Inhibition by Neutralizing Antibodies · 2012

   No notice
7. 7.

   Yu X, et al. Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27. Sci. Rep. 2015;5:13133.

   Not in our library10.1038/srep13133

8. 8.
   Structure of Severe Acute Respiratory Syndrome Coronavirus Receptor-binding Domain Complexed with Neutralizing Antibody · 2006

   No notice
9. 9.
   Structural Basis of Neutralization by a Human Anti-severe Acute Respiratory Syndrome Spike Protein Antibody, 80R · 2006

   No notice
10. 10.

    Rockx B, et al. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. J. Virol. 2008;82:3220-3235.

    Not in our library10.1128/jvi.02377-07

11. 11.

    Widjaja I, et al. Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein. Emerg. Microbes Infect. 2019;8:516-530.

    Not in our library10.1080/22221751.2019.1597644

12. 12.

    Wrapp D, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260-1263.

    Not in our library10.1126/science.abb2507

13. 13.

    Walls AC, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181:281-292.e6.

    Not in our library10.1016/j.cell.2020.02.058

14. 14.
    Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains · 2017

    No notice
15. 15.

    Gui M, et al. Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding. Cell Res. 2017;27:119-129.

    Not in our library10.1038/cr.2016.152

16. 16.

    Li W, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450-454.

    Not in our library10.1038/nature02145

17. 17.

    Walls AC, et al. Unexpected receptor functional mimicry elucidates activation of coronavirus fusion. Cell. 2019;176:1026-1039.e15.

    Not in our library10.1016/j.cell.2018.12.028

18. 18.
    Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody · 2020

    No notice
19. 19.

    Menachery VD, et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat. Med. 2015;21:1508.

    Not in our library10.1038/nm.3985

20. 20.
    Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants · 2006

    No notice
21. 21.

    Raj VS, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495:251-254.

    Not in our library10.1038/nature12005

22. 22.

    Bosch BJ, Bartelink W, Rottier PJ. Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide. J. Virol. 2008;82:8887-8890.

    Not in our library10.1128/jvi.00415-08

23. 23.

    Okba NMA, et al. Sensitive and specific detection of low-level antibody responses in mild middle east respiratory syndrome coronavirus infections. Emerg. Infect. Dis. 2019;25:1868-1877.

    Not in our library10.3201/eid2510.190051

24. 24.

    Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005;309:1864-1868.

    Not in our library10.1126/science.1116480

Cited by papers we hold 54

• Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans · 2024
  No notice
• Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming? · 2022
  Not checked
• Therapeutic antibodies under development for SARS‐CoV‐2 · 2022
  Not checked
• Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies · 2022
  No notice
• Deep learning guided optimization of human antibody against SARS-CoV-2 variants with broad neutralization · 2022
  No notice
• Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection · 2022
  No notice
• Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection · 2021
  No notice
• Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model · 2021
  No notice
• Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy · 2021
  No notice
• Blockade of SARS-CoV-2 spike protein-mediated cell–cell fusion using COVID-19 convalescent plasma · 2021
  Not checked
• Human Surfactant Protein D Binds Spike Protein and Acts as an Entry Inhibitor of SARS-CoV-2 Pseudotyped Viral Particles · 2021
  Not checked
• Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera · 2021
  Not checked
• A virus-free cellular model recapitulates several features of severe COVID-19 · 2021
  Not checked
• The Mechanisms and Animal Models of SARS-CoV-2 Infection · 2021
  Not checked
• Conformational dynamics of the Beta and Kappa SARS-CoV-2 spike proteins and their complexes with ACE2 receptor revealed by cryo-EM · 2021
  Not checked
• Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals · 2021
  No notice
• Therapeutic approaches against coronaviruses acute respiratory syndrome · 2021
  Not checked
• Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody · 2021
  No notice
• Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects · 2021
  No notice
• Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice · 2021
  No notice

and 34 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.